StockNews.AI
NUWE
StockNews.AI
3 hrs

Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management

1. Nuwellis plans to introduce a 24-hour Aquadex therapy circuit this fall. 2. The new option aids single-day outpatient sessions, enhancing scheduling efficiency. 3. Outpatient Aquadex therapy is trending, allowing fluid removal without hospital admission. 4. The company provides resources for hospitals to expand outpatient Aquadex programs. 5. Aquadex therapy offers a flexible solution for patients suffering from fluid overload.

6m saved
Insight
Article

FAQ

Why Bullish?

The introduction of a new therapy option may drive demand and market growth, likely boosting NUWE's revenue. Similar companies launching innovative solutions often see stock increases following product announcements.

How important is it?

The announcement details a strategic product expansion that enhances Nuwellis's offerings, directly impacting financial performance and growth prospects, thus holding considerable importance for stakeholders.

Why Short Term?

The planned release of the new circuit can quickly influence sales and market perception before the end of this year, similar to how past product launches have resulted in immediate stock reactions.

Related Companies

MDGLAXGNAVEO
MINNEAPOLIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall. The new circuit is designed for single-day outpatient sessions and complements the company’s existing 72-hour option that is commonly used for multi-day therapy or inpatient care. Together, these options help hospitals match supply to setting while maintaining a consistent therapy experience. Hospitals are building outpatient Aquadex programs to deliver predictable, scheduled care for patients who need fluid removal without a hospital admission. The 24-hour circuit supports that model by aligning with single-visit workflows, easing scheduling, and program planning. For patients, the goal is a straightforward same-day visit. For providers and administrators, the aim is a reliable pathway to run more efficient clinics and scale capacity. “Hospital-based outpatient Aquadex therapy is growing as a reliable option for patients who need fluid removal without a hospital admission. The 24-hour circuit supports that model with a straightforward single-visit pathway,” said John Erb, Chairman of the Board and Chief Executive Officer of Nuwellis. “This addition is about meeting sites where they are, helping teams expand access to Aquadex therapy in a clinic setting and supporting consistent, high-quality care across both outpatient and inpatient programs.” Nuwellis provides program resources for hospital-based outpatient sites, including patient identification, implementation guidance, and staff education to help teams add or expand Aquadex therapy in ambulatory settings. For more information, visit www.nuwellis.com. About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter. About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies. Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise. For further information, please contact: Investor Relations: Jenene ThomasJTC Investor RelationsNUWE@jtc.com Media Contact: Leah McMullenDirector of CommunicationsLeah.mcmullen@nuwellis.com

Related News